Clearstead Advisors’s Dr. Reddy's Laboratories RDY Stock Holding History

Clearstead Advisors’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48.4K	Buy	+3,338	New	+$45K	﹤0.01%	1510

Other funds holding RDY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Clearstead Advisors's RDY Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Dr. Reddy's Laboratories (RDY) in Q2 2026: 3,338 shares worth $48.4K. The stake represents ﹤0.01% of the portfolio and ranks #1510 among its holdings.

238 funds tracked by Wall St. Rank hold RDY as of Q2 2026.

Clearstead Advisors held 3,338 shares of Dr. Reddy's Laboratories worth $48.4K as of Q2 2026.
Dr. Reddy's Laboratories was a new Clearstead Advisors position in Q2 2026.
Dr. Reddy's Laboratories made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1510 holding.
238 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.